BMS Eyes Another Celmod Filing in Myeloma After Phase 3 Win

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

Bristol Myers claims success in study of another next-gen blood cancer drug

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 9, 2026-

Mezigdomide Regimen Boosts PFS in Relapsed/Refractory Multiple Myeloma

Investigators will present detailed findings from the phase 3 SUCCESSOR-2 trial at a later medical meeting.

Bristol Myers says second CELMoD succeeds in Phase 3

Bristol Myers Squibb has claimed another success from its CELMoD program. The oral protein degrader mezigdomide cleared the Phase 3 portion of an open-label study called SUCCESSOR-2 in relapsed or refractory multiple myeloma, the company ...